Hot Pursuit     19-Dec-22
Shilpa Medicare gains on launching breast cancer drug
Shilpa Medicare jumped 3.31% to Rs 291.55 after the drug maker said that it has introduced Capecitabine (Capebel) dispersible tablet (DT) with technology of faster dispersion within 90 seconds to treat colorectal and metastatic breast cancer.
With the introduction of Shilpa's new brand, Capebel, patients will be required to just drop the Capecitabine tablets in 100 ml water and allow the tablets to dissolve and then drink dissolved solution. Hence from 7 to 8 tablets a day, patients just need to drink 100 ml water twice daily with dissolved tablets in it.

It is expected to change the patient's compliance and will help them continue with the correct doses with ease of drinking water and getting desired outcomes.

The product is backed by required scientific proof and comparative bioequivalence studies and is approved by Central Drugs Standard Control Organisation (CDSCO).

The company is further looking to introduce Capebel 1 gm DT in various international markets through its partners and clients.

Shilpa Medicare is a global brand in manufacturing and supplying of affordable API and formulation globally in different regulated markets.

The company's reported a consolidated net loss of Rs 18.66 crore as against a net profit of Rs 19.96 crore in Q2 FY23 over Q2 FY22. Net sales declined 11% YoY to Rs 262.91 crore in the quarter ended 30 September 2022.

Previous News
  Shilpa Medicare reports consolidated net profit of Rs 4.58 crore in the December 2023 quarter
 ( Results - Announcements 08-Feb-24   17:40 )
  Indices trade with stellar gains; pharma stocks in demand
 ( Market Commentary - Mid-Session 05-Jun-24   12:33 )
  Volumes jump at Shilpa Medicare Ltd counter
 ( Hot Pursuit - 23-Dec-22   14:30 )
  Shilpa Medicare reports standalone net profit of Rs 2.70 crore in the December 2023 quarter
 ( Results - Announcements 08-Feb-24   17:29 )
  Shilpa Medicare sizzles after Unicycive gets positive results in clinical trials of OLC
 ( Hot Pursuit - 05-Jul-24   14:52 )
  Shilpa Medicare's Unit IV clears GMP inspection of Australian regulatory
 ( Corporate News - 17-Oct-23   14:35 )
  Shilpa Medicare Ltd leads gainers in 'A' group
 ( Hot Pursuit - 24-May-22   12:00 )
  Shilpa Medicare gains after TGA Australia clears GMP inspection of Telangana facility
 ( Hot Pursuit - 17-Oct-23   15:33 )
  Shilpa Medicare gains on concluding human clinical studies of Adalimumab biosimilar
 ( Hot Pursuit - 22-Aug-22   13:24 )
  Board of Shilpa Medicare recommends Interim Dividend
 ( Corporate News - 07-Mar-20   10:57 )
  Shilpa Medicare consolidated net profit declines 0.69% in the March 2017 quarter
 ( Results - Announcements 31-May-17   17:38 )
Other Stories
  Dhanlaxmi Bank gains as gross advances rises 6% YoY in Q1 FY25
  05-Jul-24   15:27
  HDFC Bank Ltd leads losers in 'A' group
  05-Jul-24   15:00
  Shilpa Medicare sizzles after Unicycive gets positive results in clinical trials of OLC
  05-Jul-24   14:52
  Manugraph India Ltd leads losers in 'B' group
  05-Jul-24   14:45
  NSE SME Nephro Care India rallies on listing day
  05-Jul-24   14:45
  ESAF SFB total deposits jumps 33% YoY in Q1
  05-Jul-24   14:43
  Utkarsh SFB deposits climb 30% YoY in Q1 FY25
  05-Jul-24   14:35
  Volumes soar at Medplus Health Services Ltd counter
  05-Jul-24   14:30
  Financials stocks slide
  05-Jul-24   14:00
  Banking stocks edge lower
  05-Jul-24   14:00
Back Top